LABORATORY CORP OF AMERICA HOLDINGS
8-K, 1999-11-03
MEDICAL LABORATORIES
Previous: RENAL CARE GROUP INC, 8-K, 1999-11-03
Next: PROJECT SOFTWARE & DEVELOPMENT INC, PRES14A, 1999-11-03






      UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                   WASHINGTON, D.C. 20549

                          FORM 8-K

                       CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934

                      OCTOBER 20, 1999
                     ------------------
              (Date of earliest event reported)


         LABORATORY CORPORATION OF AMERICA HOLDINGS
         ------------------------------------------
   (Exact name of registrant as specified in its charter)


   DELAWARE              1-11353             13-3757370
   --------              -------             ----------
(State or other         (Commission         (IRS Employer
jurisdiction of         File Number)         Identification
incorporation)                               Number)


   358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215
   -------------------------------------------------------
          (Address of principal executive offices)

                        336-229-1127
                        ------------
    (Registrant's telephone number, including area code)


<PAGE>

ITEM 5. OTHER EVENTS

On October 20, 1999, the Company issued a press release
announcing results for the quarter and nine months ended
September 30, 1999.


ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
        INFORMATION AND EXHIBITS

 (c)  Exhibit
      20  Press release of the Company dated
          October 20, 1999.


<PAGE>
                         SIGNATURES

Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.

          LABORATORY CORPORATION OF AMERICA HOLDINGS
          ------------------------------------------
                         (Registrant)

               By:/s/ BRADFORD T. SMITH
                  ------------------------------
                      Bradford T. Smith
                      Executive Vice President,
                      General Counsel, Secretary
                      and Compliance Officer



Date: November 3, 1999

<PAGE>




Laboratory Corporation of America-Registered-Trademark- Holdings
358 South Main Street
Burlington, NC   27215
Telephone: 336-584-5171

FOR IMMEDIATE RELEASE

Contact:  Pamela Sherry              Shareholder Direct:     800-LAB-0401
336-584-5171, Ext. 4855                                      www.labcorp.com



           LABORATORY CORPORATION OF AMERICA-REGISTERED TRADEMARK- REPORTS
                             THIRD QUARTER RESULTS

             Strong Operating Cash Flow Leads Key Financial Indicators


Burlington, NC, October 20, 1999 - Laboratory Corporation of America-Registered
Trademark-Holdings (LabCorp-Registered Trademark-) (NYSE: LH) today announced
results for the quarter and nine months ended September 30, 1999.

Third Quarter Results
- ---------------------
Net sales for the third quarter were $428.6 million, operating income
was $40.1 million, and net income was $17.2 million.  The basic and
diluted earnings per common share were $0.03. This compares with net
sales of $414.7 million, operating income of $34.3 million, net
income of $11.4 million, and basic and diluted earnings per common
share of $0.00 for the same period in 1998.

Earnings before interest, taxes, depreciation, and amortization
(EBITDA) were $60.3 million for the third quarter, or 14.1 percent of
net sales, versus $54.1 million, or 13.0 percent of net sales, for
the comparable period in 1998.  Operating cash flow for the quarter
was $53.1 million, compared to $24.4 million for the same quarter in
1998.

"LabCorp achieved another quarter of strong financial performance,
with positive trends continuing for key financial indicators such as
revenue, profitability, and cash collections," noted Thomas P. Mac
Mahon, president and chief executive officer.

<PAGE>
Nine Month Results
- ------------------
For the nine-month period ended September 30, 1999, LabCorp generated
net sales of $1,276.0 million, operating income of $116.6 million,
and net income of $51.2 million.  For the same period in 1998, net
sales were $1,204.8 million, operating income was $101.0 million, and
net income $33.5 million.  The basic and diluted earnings per common
share were $0.11 in 1999 compared to $0.00 in 1998.  EBITDA for the
first nine months of 1999 was $178.9 million, or 14.0 percent of net
sales, versus $162.7 million, or 13.5 percent of net sales, for the
comparable period in 1998.  Operating cash flow was $128.9 million.

"By focusing on the implementation of our strategic plan, we have
strengthened our base business, reduced days sales outstanding by
seven days since the beginning of the year, and exceeded total
operating cash flow for 1998 in the first nine months of 1999," said
Mr. Mac Mahon.  "We have also continued to build our leadership
position in key esoteric testing areas such as genotyping and
phenotyping."

A live broadcast of LabCorp's quarterly conference call will be
available online at www.labcorp.com or at www.streetfusion.com, on
October 21, 1999, beginning at 9:00 a.m. Eastern Daylight Time, with
an online rebroadcast continuing through November  30, 1999.

The Company noted that each of the above forward-looking statements
was subject to change based on various important factors, including
without limitation, competitive actions in the marketplace and
adverse actions of governmental and other third-party payors.
Further information on potential factors that could affect the
Company's financial results is included in the Company's Form 10-K
for the year ended December 31, 1998 and subsequent SEC filings.

Laboratory Corporation of America-Registered Trademark- Holdings
(LabCorp-Registered Trademark-) is a national clinical laboratory with
annual revenues of $1.6 billion in 1998.  With 18,000 employees and over
100,000 clients nationwide, the company offers more than 2,000 clinical
tests, ranging from simple blood analyses to more sophisticated
technologies. Included in LabCorp's network of 25 major laboratories are
three Centers of Excellence. The Center for Molecular Biology and Pathology,
in Research Triangle Park (RTP), North Carolina, develops applications
for polymerase chain reaction (PCR) technology. Its Center for
Occupational Testing in RTP is the world's largest substance abuse
testing facility, and the Center for Esoteric Testing in Burlington,
North Carolina, performs the largest volume of rare analyses in the
network. LabCorp's clients include physicians, state and federal
governments, managed care organizations, hospitals, clinics,
pharmaceutical and Fortune 1000 companies, and other clinical
laboratories.
                           - End of Text -

                         - Table to Follow -

<PAGE>
<TABLE>
                           LABORATORY CORPORATION OF AMERICA HOLDINGS
                                Summarized Financial Information
                           (Dollars in millions, except per share data)

                                         (Unaudited)          (Unaudited)
                                     Three Months Ended     Nine Months Ended
                                        September 30,         September 30,
                                     -------------------   -------------------
                                        1999      1998        1999      1998
                                     -------------------   -------------------
<S>                                 <C>       <C>         <C>        <C>
STATEMENT OF OPERATIONS DATA:
Net sales                            $ 428.6   $ 414.7     $ 1,276.0  $ 1,204.8
Cost of sales                          265.2     270.3         796.9      783.9
Selling, general and administrative    115.6     102.4         339.1      297.1
Amortization of intangibles
  and other assets                       7.7       7.7          23.4       22.8
                                      ------    ------      --------   --------
Operating income                        40.1      34.3         116.6      101.0
                                      ------    ------      --------   --------
Earnings before income taxes            27.8      22.3          82.6       66.6

Provision for income taxes             (10.6)    (10.9)        (31.4)     (33.1)
                                      ------    ------      --------   --------
Net earnings                            17.2      11.4          51.2       33.5

Less preferred stock dividends and
  accretion of mandatorily
   redeemable preferred stock           13.1      11.3          37.1       34.0
                                      ------    ------      --------   --------
Net income (loss) attributable
   to common shareholders             $  4.1    $  0.1      $   14.1   $   (0.5)
                                      ======    ======      ========   ========
Basic and diluted earnings
   (loss) per share (1)               $  0.03   $  0.00     $    0.11  $  (0.00)
                                      =======   =======     =========  ========

(1)  Basic and diluted earnings (loss) per common share are based on
    the weighted average number of shares outstanding during the three-
    and nine-month periods ended September 30, 1999, of 127,072,911 and
    126,493,066 shares, respectively, and the weighted average number of
    shares outstanding during the three- and nine-month periods ended
    September 30, 1998, of 125,199,880 and 124,704,341 shares,
    respectively.


<PAGE>
                                         (Unaudited)
                                      Nine Months Ended    Year Ended
                                        September 30,      December 31,
                                      -----------------    ------------
                                            1999               1998
                                      -----------------    ------------
BALANCE SHEET DATA:
Cash and cash equivalents                $    19.7          $    22.7
Accounts receivable, net                     360.7              375.4
Property, plant & equipment                  272.2              259.2
Intangible assets, net                       812.6              836.2
Other assets                                 146.8              147.4
                                         ---------          ---------
                                         $ 1,612.0          $ 1,640.9
                                         =========          =========

Total bank debt                          $   584.6          $   643.8
Other liabilities                            304.4              315.9
Redeemable preferred stock                   550.0              526.8
Shareholders' equity                         173.0              154.4
                                         ---------          ---------
                                         $ 1,612.0          $ 1,640.9
_______________________________          =========          =========

</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission